Hello everyone,
I work in the Policy and Campaigns Team at Breast Cancer Care.
Atezolizumab is currently being considered by the National Institute for Health and Care Excellence (NICE) to be made available on the NHS in England for treating previously untreated, locally advanced or metastatic, triple negative, PD-L1 positive breast cancer.
We are gathering evidence to contribute to NICE’s patient carer groups’ submissions and we’d like to speak to anybody who is being or has been treated with atezolizumab , to help inform our response on what access to this drug would mean to women with secondary breast cancer.
We’re looking for responses by 21 March.
If you’re able to help, please email campaigns@breastcancercare.org.uk
Thanks,
Erin